1427043-08-0Relevant articles and documents
Discovery of (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid and congeners as highly potent inhibitors of human arginases i and II for treatment of myocardial reperfusion injury
Van Zandt, Michael C.,Whitehouse, Darren L.,Golebiowski, Adam,Ji, Min Koo,Zhang, Mingbao,Beckett, R. Paul,Jagdmann, G. Erik,Ryder, Todd R.,Sheeler, Ryan,Andreoli, Monica,Conway, Bruce,Mahboubi, Keyvan,D'Angelo, Gerard,Mitschler, Andre,Cousido-Siah, Alexandra,Ruiz, Francesc X.,Howard, Eduardo I.,Podjarny, Alberto D.,Schroeter, Hagen
, p. 2568 - 2580 (2013/05/21)
Recent efforts to identify treatments for myocardial ischemia reperfusion injury have resulted in the discovery of a novel series of highly potent α,α-disubstituted amino acid-based arginase inhibitors. The lead candidate, (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid, compound 9, inhibits human arginases I and II with IC50s of 223 and 509 nM, respectively, and is active in a recombinant cellular assay overexpressing human arginase I (CHO cells). It is 28% orally bioavailable and significantly reduces the infarct size in a rat model of myocardial ischemia/reperfusion injury. Herein, we report the design, synthesis, and structure-activity relationships (SAR) for this novel series of inhibitors along with pharmacokinetic and in vivo efficacy data for compound 9 and X-ray crystallography data for selected lead compounds cocrystallized with arginases I and II.